Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study.
Study Design
- Тип исследования
- Controlled Clinical Trial
- Популяция
- Patients with Crohn's disease
- Вмешательство
- Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study. Washed microbiota transplantation (WMT)
- Препарат сравнения
- Pre-treatment baseline
- Первичный исход
- Clinical remission and multi-omics changes
- Направление эффекта
- Positive
- Риск систематической ошибки
- Moderate
Abstract
BACKGROUND: Fecal microbiota transplantation (FMT) is a promising therapeutic approach for treating Crohn's disease (CD). The new method of FMT, based on the automatic washing process, was named as washed microbiota transplantation (WMT). Most existing studies have focused on observing the clinical phenomena. However, the mechanism of action of FMT for the effective management of CD-particularly in-depth multi-omics analysis involving the metagenome, metatranscriptome, and metabolome-has not yet been reported. AIM: To assess the efficacy of WMT for CD and explore alterations in the microbiome and metabolome in response to WMT. METHODS: We conducted a prospective, open-label, single-center clinical study. Eleven CD patients underwent WMT. Their clinical responses (defined as a decrease in their CD Activity Index score of > 100 points) and their microbiome (metagenome, metatranscriptome) and metabolome profiles were evaluated three months after the procedure. RESULTS: Seven of the 11 patients (63.6%) showed an optimal clinical response three months post-WMT. Gut microbiome diversity significantly increased after WMT, consistent with improved clinical symptoms. Comparison of the metagenome and metatranscriptome analyses revealed consistent alterations in certain strains, such as Faecalibacterium prausnitzii, Roseburia intestinalis, and Escherichia coli. In addition, metabolomics analyses demonstrated that CD patients had elevated levels of various amino acids before treatment compared to the donors. However, levels of vital amino acids that may be associated with disease progression (e.g., L-glutamic acid, gamma-glutamyl-leucine, and prolyl-glutamine) were reduced after WMT. CONCLUSION: WMT demonstrated therapeutic efficacy in CD treatment, likely due to the effective reconstruction of the patient's microbiome. Multi-omics techniques can effectively help decipher the potential mechanisms of WMT in treating CD.
Used In Evidence Reviews
Similar Papers
The Cochrane database of systematic reviews · 2018
Enteral nutritional therapy for induction of remission in Crohn's disease.
Gut · 2010
MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.
The Cochrane database of systematic reviews · 2007
Enteral nutritional therapy for induction of remission in Crohn's disease.
Journal of pediatric gastroenterology and nutrition · 2000
Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease.
Alimentary pharmacology & therapeutics · 2003
Review article: nutrition and adult inflammatory bowel disease.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 1997